Silverarc Capital Management, LLC Viridian Therapeutics, Inc.\De Transaction History

Silverarc Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$11.12 - $22.5 $33,360 - $67,500	3,000 Added 6.32%	50,438 $1.1 Million
Q3 2023 Nov 13, 2023	BUY	$15.16 - $24.7 $36,960 - $60,218	2,438 Added 5.42%	47,438 $727,000
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $194,530 - $255,725	8,619 Added 23.69%	45,000 $1.07 Million
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $835,860 - $1.26 Million	33,381 Added 1112.7%	36,381 $925,000
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $56,340 - $89,220	3,000 New	3,000 $87,000
Q2 2022 Jul 25, 2022	SELL	$9.55 - $19.0 $1.2 Million - $2.4 Million	-126,136 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$16.79 - $20.88 $39,120 - $48,650	2,330 Added 1.88%	126,136 $2.33 Million
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $277,443 - $381,152	17,728 Added 16.71%	123,806 $2.45 Million
Q3 2021 Nov 15, 2021	BUY	$10.69 - $18.2 $830,388 - $1.41 Million	77,679 Added 273.53%	106,078 $1.75 Million
Q2 2021 Aug 16, 2021	BUY	$14.34 - $18.67 $11,658 - $15,178	813 Added 2.95%	28,399 $519,000
Q1 2021 May 18, 2021	BUY	$15.5 - $24.93 $427,583 - $687,718	27,586 New	27,586 $461,000

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $806M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.